Partnering with Synageva
Product Development Collaborations
Synageva’s senior team has been involved in the development and commercialization of many novel protein therapeutics marketed to date for rare diseases. We are selectively creating relationships and product development collaborations that benefit from this therapeutic expertise and which leverage the scientific and operational advantages of our proprietary protein technologies. Examples of these collaborations include our partnerships with:
Mitsubishi Tanabe Pharma Corporation
Synageva has an active licensing program seeking to create partnerships with industry and academia. Our in-licensing efforts are focused on adding products to our portfolio that have the potential to treat rare and ultra-rare diseases. Our primary interest is in novel therapeutics, although we are also interested in compelling biobetter products that have the potential to meet unmet medical need by significantly increasing the standard of care and making a meaningful impact on the lives of patients.
Synageva’s out-licensing has centered on a significant portfolio of advanced programs that target large specialty markets. These assets include both biosimilar and biobetter products that fall outside of Synageva’s core strategic focus. We are actively seeking partnerships for the further development and commercialization of these products.
Submit a Partnering Inquiry to Synageva
FUZEON® (enfuvirtide) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. The product was developed by Trimeris in collaboration with its exclusive licensee, Roche. Commercialization of FUZEON began in 2003 and it is manufactured and sold worldwide by Roche. Following the merger with Trimeris in November 2011, Synageva receives royalties from Roche on global product sales.
For more information on FUZEON, please visit www.FUZEON.com.
FUZEON is a registered trademark of Hoffmann-La Roche, Inc. All rights reserved.